Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAZ053 with or without PDR001 in advanced solid tumors
NCT02936102Phase 1Terminated
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of FAZ053 in solid tumor (advanced stage), triple-negative breast cancer (TNBC), chordoma and 1 more (2 arms), sponsored by Novartis. Primary endpoints: Adverse Events and Serious Adverse Events, Dose Limiting Toxicities and 2 more. Started Oct 2016; status: terminated.
02
Drugs
FAZ053
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)chordomaalveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT02936102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936102.